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Abstract
Introduction Bemiparin has shown to be eVective and
safe in clinical trials in total knee or hip replacement.
Materials and methods We conducted a prospective,
open, multicentre, uncontrolled study to audit the util-
isation patterns of bemiparin 3,500 IU/day, Wrst dose
administered 6 h after surgery, in 1,009 patients under-
going total hip or knee replacement surgery in stan-
dard clinical practice. We analysed rates of
documented symptomatic venous thromboembolism
(VTE) [deep-vein thrombosis (DVT) and pulmonary
embolism (PE)] conWrmed by objective methods,
major bleeding, death, thrombocytopaenia and other
adverse events up to 6 weeks.
Results Rate of documented symptomatic DVT was
0.3% (95% CI, 0.1–0.9%). No cases of documented PE
were reported. There were 14 (1.4%) major bleedings
(95% CI, 0.8–2.3%). Neuraxial anaesthesia was used in
937 (92.9%) patients. There were no cases of spinal
haematoma, fatal bleeding or bleeding in critical organs.
There were 6 (0.6%) cases of mild thrombocytopaenia,
which did not require treatment discontinuation. No
cases of severe type II heparin-induced thrombocyto-
paenia were observed. There were no deaths during
bemiparin prophylaxis. The median length of hospitali-
sation was 9 days and 92.5% of patients continued pro-
phylaxis post-hospitalisation for a total median time of
38 days. There were no thromboembolic or bleeding
complications during post-hospitalisation prophylaxis.
Postoperative start of prophylaxis with bemiparin per-
mitted that 29.3% of patients could be admitted to hos-
pital the same day of the intervention.
Conclusion Bemiparin prophylaxis, started 6 h after
surgery and given for 5–6 weeks after total hip or knee
replacement, was associated with low rates of VTE,
major bleeding and other adverse events in normal
clinical practice. Bemiparin thromboprophylaxis
started 6 h after surgery makes neuraxial anaesthesia/
analgesia procedures easier, without compromising
eYcacy.
Keywords Bemiparin · Heparin · Knee replacement · 
Hip replacement · Thromboprophylaxis · 
Venous thromboembolism · Deep-vein thrombosis · 
Pulmonary embolism
Introduction
Patients undergoing major orthopaedic surgery, such
as total knee replacement (TKR) or total hip replace-
ment (THR) surgery, represent a group at particu-
larly high risk of venous thromboembolism (VTE) [9,
15]. The risk remains high for several weeks after sur-
gery [9]. In these patients, routine chemical thrombo-
prophylaxis has been the standard of care for the past
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pulmonary embolism (PE) [5]. Low-molecular-weight
heparin (LMWH) is signiWcantly better than warfarin
or aspirin in preventing deep-vein thrombosis (DVT)
after major orthopaedic surgery [23]. Mechanical
means of prophylaxis could provide an additional
eYcacy [9, 19]. The beneWts of neuraxial anaesthesia
(i.e. spinal or epidural) are also well established
[1, 18].
The widespread use of thromboprophylaxis and
neuraxial anaesthesia in patients undergoing major
orthopaedic surgery—these procedures are used in
60–95% of all THR or TKR surgeries [8, 14]—makes
it necessary to develop new strategies to enhance
safety in these patients. Neuraxial anaesthesia should
generally be avoided in patients whose preoperative
haemostasis is impaired by antithrombotic drugs [9],
because of the increased risk of spinal haematoma [11,
21]. In order to avoid preoperative impaired haemo-
stasis, thus minimising the risk of spinal haematoma
and intraoperative bleeding, it would be reasonable to
start prophylaxis several hours after surgery, when-
ever the eYcacy of LMWH should not be compro-
mised [20, 24].
Bemiparin is a new second-generation LMWH [16]
that has shown greater eYcacy than standard heparin
in a comparative clinical trial conducted by Kakkar
et al. in the prevention of VTE after THR surgery [12].
Bemiparin may be started before or after surgery,
whereas recommendations for other LMWHs in
Europe primarily involve preoperative initiation [4].
In a recent, comparative clinical trial with enoxapa-
rin in total TKR, bemiparin 3,500 IU/day started 6 h
after surgery showed a non-signiWcant trend towards a
lower incidence of documented symptomatic VTE as
compared with enoxaparin 4,000 IU/day started 12 h
before surgery, with a similar safety proWle [14].
This observational study was designed to gain addi-
tional clinical experience with postoperative start of
bemiparin prophylaxis in a large population of ortho-
paedic patients in normal clinical practice.
Materials and methods
This study was designed as a prospective, uncontrolled,
open-label, multicentre, observational “real life”
assessment of bemiparin, started 6 h after surgery, in
patients undergoing TKR or THR surgery. The study
was conducted according to the Spanish requirements
for observational studies (Circular 4/2000 of the Span-
ish Medicines Agency) and European Guidelines
(CPMP/PhVWP/109/99/corr).
Any patient undergoing TKR or THR surgery was
eligible for inclusion in the study. There were no pre-
established exclusion criteria in the protocol.
All patients received once daily subcutaneous injec-
tions of bemiparin 3,500 IU, starting 6 h after surgery,
that were administered during the risk period accord-
ing to the physician’s criteria. The extent of exposure
was shown by the median days (Wrst and third quartile)
of bemiparin prophylaxis. Non-pharmacological treat-
ments, such as active or passive mobilisation, elastic
bandages and/or intermittent pneumatic compression
devices, were used according to the usual practice at
each centre and were recorded in the case report form.
The primary eVectiveness outcome was documented
symptomatic VTE, including DVT, PE or both. If VTE
was clinically suspected, it had to be conWrmed by
objective methods (i.e. Doppler ultrasound or ascend-
ing contrast venography for DVT, high-probability
lung scanning, pulmonary angiography, helical com-
puted tomography for non-fatal PE, or necropsy in
cases of suspected fatal PE). The decision whether or
not to perform conWrmatory tests was left to physi-
cians’ criteria.
The primary safety endpoint was the occurrence of
major bleeding, deWned as clinically overt bleeding
associated with fall in haemoglobin of at least 2 g/dl or
requirement of a transfusion of 2 or more units of
blood, bleeding in critical organs (intracranial, spinal,
retroperitoneal or intraocular bleeding), fatal bleeding,
bleeding requiring reoperation to control bleed, or any
bleeding requiring treatment cessation. Minor bleeding
was any other overt bleeding that did not fulWl the cri-
teria of major bleeding.
The following analytical parameters were tested:
haematocrit, hemoglobin, platelets, AST (aspartate
aminotransferase), ALT (alanine aminotransferase)
and GGT (gamma-glutamyl transpeptidase). Throm-
bocytopaenia was deWned as a platelet count < 150,000/
mm3 during bemiparin prophylaxis. Postoperative
anaemia was deWned as a haemoglobin value <12 g/dl
at hospital discharge. The incidence of death, allergic
reactions, wound haematoma/bruising and reactions at
injection site were also assessed.
Three visits were scheduled: the Wrst one the day of
surgery (baseline), the second one at the time of hospi-
tal discharge (outcome assessment visit), and the third
one during the Wrst outpatient visit (follow-up visit),
according to standard clinical practice.
Ninety-Wve percent conWdence intervals were calcu-
lated for the rates of VTE, major and minor bleeding
events, thrombocytopaenia, deaths and allergic reac-
tions. These calculations were performed using SPSS
software, version 7.5.123
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Between November 2001 and March 2003, 1,009
patients were enrolled in 23 Spanish centres. Baseline
characteristics of patients included in the study are
shown in Table 1. Among the 1,009 patients included,
653 (64.7%) underwent TKR surgery and 356 (35.3%)
underwent THR surgery. Mean age of patients
included was 70.9 years. Most patients were females
(66.8%), and mean body weight was 76.9 kg. Neuraxial
anaesthesia, alone [882 patients (87.4%)] or in combi-
nation with general anaesthesia [55 patients (5.5%)],
was administered to 937 (92.9%) patients. Patients
received bemiparin prophylaxis for a median time of
8 days during hospitalisation. More than 90% of
patients continued extended outpatient prophylaxis
with bemiparin 3,500 IU/day for 30 additional days
(median) (Table 1). Twenty-nine percent of patients
were admitted to hospital on the same day of surgery
(Table 1).
Table 1 Demographic data and other characteristics
Mean, median and percents are calculated for assessable patients













Age, mean (SD) 71.6 (6.8) 69.4 (11.7) 70.9 (8.5) 547
Sex, n (%) 1,007
Male 177 (27.1) 157 (44.3) 334 (33.2)
Female 476 (72.9) 197 (55.7) 673 (66.8)
Weight (kg), mean (SD) 76.7 (10.9) 77.5 (11.9) 76.9 (11.2) 928
Height (cm), mean (SD) 162.3 (8.7) 165.9 (8.5) 163.4 (8.8) 898
BMI, kg/m2, mean (SD) 29.2 (4.7) 28.2 (3.8) 28.9 (4.1) 898
Admission on the same day 
of surgery, n (%)
167 (29.5) 74 (28.9) 241 (29.3) 822
Hospitalisation days, median 
(Wrst, third quartiles) 
9.0 (8, 12) 9.0 (8, 12) 9.0 (8, 12) 867
Surgery information
Type of surgery, n (%) 945
Primary joint replacement 595 (96.7) 297 (90) 892 (94.4)
Revision surgery 20 (3.3) 33 (10.0) 53 (5.6)
Type of prosthesis, n (%) 968
Cemented prosthesis 530 (83.9) 90 (26.8) 620 (64.1)
Uncemented prosthesis 102 (16.1) 246 (73.2) 348 (35.9)
Type of anesthesia used, n (%) 1,009
Neuraxial 589 (90.2) 293 (82.3) 882 (87.4)
Spinal 351 (53.8) 205 (57.6) 556 (55.1)
Epidural 238 (36.4) 88 (24.7) 326 (32.3)
Combined neuraxial–general 35 (5.4) 20 (5.6) 55 (5.5)
General 29 (4.4) 43 (12.1) 72 (7.1)
Operative transfusions, n (%) 980
Autologous 80 (12.2) 26 (7.3) 106 (10.8)
Heterologous 89 (13.6) 69 (19.4) 158 (16.1)
Both 5 (0.8) 2 (0.6) 7 (0.7)
Tourniquet and/or careful haemostasis 
previous to wound closure, n (%)
521 (82.1) 152 (52.1) 673 (72.6) 927
Surgery duration, minutes, mean (SD) 92.0 (33.4) 103.3 (29.0) 95.7 (32.4) 783
Postoperative period
Time to ambulation, days, mean (SD) 3.65 (2.37) 4.34 (3.20) 3.87 (2.68) 917
Elastic graduated pressure stockings, n (%) 218 (37.6) 43 (14.5) 261 (29.8) 876
Intermittent pneumatic compression, n (%) 45 (7.8) 1 (0.3) 46 (5.3) 876
Patient exposure to bemiparin 3,500 IU 922
In-hospital doses, median 
(Wrst, third quartiles)
8 (7, 10) 8 (6, 10) 8 (6, 10)
Out-hospital doses, median 
(Wrst, third quartiles)
30 (26, 36) 30 (26, 34) 30 (26, 36)
Extended prophylaxis out-hospital, n (%) 589 (90.5) 342 (96.3) 931 (92.5) 1,006
Observation period, median 
(Wrst, third quartiles)
39 (32, 43) 39 (31, 42) 39 (32, 43) 843123
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discharge. Three (0.3%; 95% CI, 0.1–0.9%) of the 1,009
patients experienced symptoms of DVT (Table 2). All
of them occurred while in the hospital, 6–9 days after
surgery. The events were two proximal DVTs after
TKR and one distal DVT after THR, which were con-
Wrmed by Doppler ultrasound. One patient undergoing
KR developed symptoms of PE on post-operative day
4. However, the event was ruled out by lung scanning.
There were no cases of VTE after hospital discharge.
Major bleeding occurred in 14 (1.4%; 95% CI, 0.8–
2.3%) of the 1,009 patients (Table 2). All major bleed-
ing events occurred during hospitalisation, and included
ten cases of excessive wound bleeding, three haemarth-
roses of the prosthetic joint, and one gastrointestinal
bleeding (coVee ground vomiting). None were fatal. Of
all major bleedings, one excessive wound bleeding
occurred before the Wrst bemiparin dose, and required
reoperation for control. The major gastrointestinal
bleeding occurred in one patient with a clinical history
of grade III gastroesophageal reXux and hiatal hernia
who was concomitantly receiving an intravenous non-
steroidal anti-inXammatory drug (NSAID). Both medi-
cations, NSAID and bemiparin, were stopped. Two
days after patient recovery, bemiparin was re-started
and the adverse event did not recur. A total of 937
(92.9%) patients received neuraxial anaesthesia, and no
cases of spinal haematoma were reported.
There were no deaths during the treatment period
with bemiparin. Thrombocytopaenia was seen in 6
(0.6%; 95% CI, 0.2–1.3%) of the 1,009 patients
included (Table 2). Thrombocytopaenia ranged from
80,000/mm3 to 135,000/mm3, and none of this required
treatment discontinuation. There were no cases of
severe heparin-induced thrombocytopaenia (HIT type-
II). Mild to moderate postoperative anaemia (Hb 8–
12 g/dl) was shown in 484 (48.0%) patients. Only three
(0.3%) patients had haemoglobin levels <8 g/dl during
the study. Mild, transient increases in serum amin-
otransferases, always less than three times the upper
normal limit, were reported in 2.1% (AST), 4.0%
(ALT) and 3.2% (GGT) of patients included. None of
the cases were clinically signiWcant and none of them
required treatment discontinuation. A minor allergic
reaction, consisting of mild urticaria around the injec-
tion site, was seen in one patient (0.1%; 95% CI, 0.0–
0.6%). Treatment was not discontinued. There were no
cases of systemic or general allergic reactions. Among
all patients included, 16.1% developed surgical wound
haematoma/bruising (95% CI, 13.8–18.5%), and none
of them needed local reintervention or prolonged hos-
pitalisation. Overall, 1.5% patients experienced surgi-
cal wound infection. Only 6 of 23 centres reported any
surgical wound infection. Injection site reactions were
reported in 20% of patients. Most of these reactions
were mild ecchymoses. There were no cases of injec-
tion site haematomas greater than 5 cm in diameter or
requiring treatment discontinuation. There were no
rare or unexpected adverse drug reactions to bemipa-
rin during the study.
Follow-up
A total of 931 patients (92.5%) received extended out-
patient prophylaxis. There were no thromboembolic or
haemorrhagic complications during the time from hospi-
tal discharge to the follow-up visit. A 72-year-old male
patient with clinical history of ischaemic heart disease
died from an acute myocardial infarction 2 months after
TKR surgery and 20 days after the last bemiparin dose.
Discussion
A low incidence of documented symptomatic VTE was
seen when bemiparin was started 6 h after surgery in
Table 2 Overall eVectiveness and safety during prophylaxis period
VTE venous thromboembolism, DVT deep-vein thrombosis, PE pulmonary embolism
Variable Knee replacement 
N = 653 [% (n)]
Hip replacement 
N = 356 [% (n)]
Total Bemiparin 




0.3 (2) 0.3 (1) 0.3 (3) 0.1–0.9
Proximal DVT 0.3 (2) 0 (0) 0.2 (2) 0.0–0.7
Distal DVT 0 (0) 0.3 (1) 0.1 (1) 0.0–0.6
Non-fatal PE 0 (0) 0 (0) 0 (0) 0.0–0.4
Fatal PE 0 (0) 0 (0) 0 (0) 0.0–0.4
Major bleeding 0.8 (5) 2.5 (9) 1.4 (14) 0.8–2.3
Minor bleeding 7.5 (49) 9.0 (32) 8.0 (81) 6.4–9.9
Death by any cause 0 (0) 0 (0) 0 (0) 0.0–0.4
Thrombocytopaenia 0.5 (3) 0.8 (3) 0.6 (6) 0.2–1.3123
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symptomatic VTE during hospitalisation in our obser-
vational study was 0.3% (two proximal DVTs, one dis-
tal DVT, and no cases of documented symptomatic
PE), which is entirely comparable and even lower than
the incidence of symptomatic VTE reported with other
antithrombotic drugs during short-term prophylaxis
after major orthopaedic surgery [22]. It must be
pointed out that comparisons of the results of observa-
tional studies with those of clinical trials should be
interpreted with caution, given the methodological
diVerences between the two types of studies.
In our study, more than 90% of patients received
extended prophylaxis with bemiparin for a median time
of 38 days. No cases of VTE were reported during
extended bemiparin prophylaxis after hospital discharge.
The incidence is lower than the 1.3% (range 0–3.5%)
rate of symptomatic VTE reported in a recent meta-anal-
ysis with other LMWH during extended prophylaxis
after TKR or THR [6], or the 3.3% incidence with pla-
cebo in the same meta-analysis [6], and lower than the
0.3% incidence of symptomatic VTE during extended
prophylaxis with fondaparinux [7]. The duration of pro-
phylaxis used in our study is consistent with current rec-
ommendations [9] including the use of prolonged
prophylaxis for up to 4–5 weeks in patients undergoing
THR surgery. The need of prolonged thromboprophy-
laxis after TKR is still in debate [9]. Nevertheless, a
recent meta-analysis showed that, among patients under-
going THR or TKR, extended-duration prophylaxis sig-
niWcantly reduced the frequency of symptomatic venous
thromboembolism [6]. The reduction in risk of symptom-
atic VTE was higher in THR than in TKR [6].
We found a low incidence of major bleeding compli-
cations—1.4%—which agrees with the reported inci-
dence for short-term in-hospital prophylaxis with
bemiparin during clinical trials in major orthopaedic sur-
gery [12, 14]. This rate is lower than the 2.7% incidence
reported with fondaparinux and similar to the 1.7% inci-
dence reported with enoxaparin during short-term in-
hospital prophylaxis after major orthopaedic surgery in
selected populations from clinical trials [3]. In addition,
no major bleeding complications were reported during
extended outpatient prophylaxis with bemiparin in our
study, which is similar to the 0.1% incidence of major
bleeding found in a recent meta-analysis of extended
LMWH prophylaxis in TKR or THR surgery [6], and
lower than the 2.4% incidence seen during extended
outpatient prophylaxis with fondaparinux [7].
In our observational study, there were no deaths dur-
ing the study period. All cases of thrombocytopaenia
were mild to moderate and did not require treatment
discontinuation. There were no cases of type-II severe
thrombocytopaenia. The rates of surgical wound haema-
toma/bruising and injection site reactions were similar to
those previously reported with bemiparin, and lower
than reported with enoxaparin in a comparative clinical
trial in TKR [14]. No rare or unexpected adverse drug
reactions to bemiparin occurred during the study.
In our study, nearly one-third of patients included
were admitted to hospital the same day of surgery,
instead of on the evening before the procedure, thus
potentially reducing hospital stay costs. In a recent
pharmacoeconomic study, bemiparin administered
postoperatively was a dominant strategy over enoxapa-
rin administered preoperatively, oVering better out-
come at lower cost [10].
In our study, neuraxial anaesthesia was used alone
or combined with general anaesthesia in more than
90% of patients, and no cases of spinal haematoma
were reported. Although the timing of the Wrst admin-
istration of thromboprophylaxis is controversial [17], it
is recognised that bemiparin administration started 6 h
after surgery does not compromise eYcacy [14], and is
compatible with neuraxial anaesthesia techniques [11].
On the contrary, patients on preoperative LMWH
thromboprophylaxis can be assumed to have altered
coagulation. In these patients, needle placement
should occur at least 10–12 h after the LMWH dose
[11]. Thromboprophylaxis started less than 6 h after
surgery may increase the risk of bleeding without
improved eYcacy [17]. Initiation 12–24 h postopera-
tively may be less eVective than initiation at 6 h [17].
This study has several methodological limitations.
However, the results of this observational study should
be interpreted in the setting of normal clinical practice.
This type of studies add information that is not avail-
able in randomised controlled trials [2] where exclu-
sion criteria, limited sample size and use in speciWc
clinical situation leads to signiWcant loss of useful prag-
matic data. Therefore, we were able to assess the “real
life” eVect of bemiparin in a large audit of orthopaedic
patients. Clinical endpoints are of major value to assess
the eVects of a new drug in clinical studies on the pre-
vention of VTE [13].
In conclusion, bemiparin prophylaxis, started 6 h
after surgery and given for 5–6 weeks after THR or
TKR was associated with low rates of VTE, major
bleeding and other adverse events in normal clinical
practice. Moreover, bemiparin thromboprophylaxis
started 6 h after surgery minimises the risk of spinal
haematoma and makes neuraxial anaesthesia/analgesia
procedures easier, without compromising eYcacy.
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